Under the Paperviork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10563935			
Filing Date		2006-01-09			
First Named Inventor	Huber	rt C. F. MARTENS			
Art Unit		2627			
Examiner Name					
Attorney Docket Number		NI 030748			

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date		Name of Patentee or Applicant of cited Document			Lines where ges or Releva
	1	6451402		2002-09-17	NEE				
	2	6434107	B1	2002-08-13	ARTIGALAS I	ET AL			
	3	5676854		1997-10-14	INUI, ET AL				
	4	5914926		1999-06-22	MAENO ET A	L			
If you wisl	h to a	dd additional U.S. Pater	t citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date		Name of Patentee or Applicant of cited Document			Lines where ges or Releva
	1								
If you wis	h to a	d additional U.S. Publi:	shed Ap	plication cita	tion information	please click the Ad	d button	Add	
				FOREIGN P	ATENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		d Publication le4 Date	Name of Patente Applicant of cited Document	e or V	here Rel	or Relevant

U.S.PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10563935		
iling Date		2006-01-09		
irst Named Inventor Huber		rt C. F. MARTENS		
rt Unit		2627		
xaminer Name				
ttorney Docket Numb	er	NL030748		

Date Considered

	ľ			ļ	2000 01 21			-		
	2	1067535	₽	A2	2001-01-10	PIONEER CORP				
	3	03083845	wo	A1	2003-10-09	KPENV				
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add			
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look now, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and offic country where published.										

2003.07-24 KDEMV

E

MO

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

*EXAMINER: Initial if	reference considered, whel	ther or not citation is in conform	ance with MPEP 609.	. Draw line through a
citation if not in confo	rmance and not considered	I. Include copy of this form with	next communication	to applicant

1 Sex Kind Cooles of USPTO Patent Documents at year LISETQ.GQ(or MEEP 901.6. <sup>2</sup> Ester office that issued the document, by the Nov-liter code (WIPO Standard ST3.) <sup>2</sup> For Juspines patent concurrent, be reduced not they year of the Empore range specially extra all number of the patent concern, and for the year of the Empore range specially extra all number of the patent document, and for the special spec

Evaminer Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10563935		
Filing Date		2006-01-09		
First Named Inventor	Hubert C. F. MARTENS			
Art Unit		2627		
Examiner Name				
Attorney Docket Numb	er	NL030748		

#### CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 02	to make	the	appropriate	coloction/	el·

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

To the agricult.									
	Signature	/Michael E. Belk/	Date (YYYY-MM-DD)	2007-03-19					
	Name/Print	Michael F Relk	Registration Number	33.357					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.